

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
08 December 2022 (08.12.2022)



(10) International Publication Number
WO 2022/253907 A1

(51) International Patent Classification:

C07D 401/14 (2006.01) C07C 309/29 (2006.01)
C07C 55/08 (2006.01) C07C 309/30 (2006.01)
C07C 57/145 (2006.01) A61P 35/00 (2006.01)

TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/EP2022/064935

(22) International Filing Date:

01 June 2022 (01.06.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2107924.9 03 June 2021 (03.06.2021) GB

(71) Applicants: **SENTINEL ONCOLOGY LIMITED** [GB/GB]; 181 Science Park, Milton Road, Cambridge Cambridgeshire CB4 0GJ (GB). **PHARMAENGINE, INC.** [CN/CN]; 11F, 10 Minsheng East Road, Sec. 3, Taipei, 10480 (TW).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))
- of inventorship (Rule 4.17(iv))

Published:

- with international search report (Art. 21(3))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(72) Inventors: **MAJOR, Meriel**; c/o Sentinel Oncology Limited, 181 Science Park, Milton Road, Cambridge Cambridgeshire CB4 0GJ (GB). **TRAVERS, Stuart**; c/o Sentinel Oncology Limited, 181 Science Park, Milton Road, Cambridge Cambridgeshire CB4 0GJ (GB). **PARKER, Jake**; Onyx Scientific, Units 97-98, Silverbriar, Sunderland Enterprise Park East, Sunderland Tyne and Wear SR5 2TQ (GB). **NORTHERN, Julian**; Onyx Scientific, Units 97-98, Silverbriar, Sunderland Enterprise Park East, Sunderland Tyne and Wear SR5 2TQ (GB).

(74) Agent: **BAJJON, Alexander**; Schlich, 9 St Catherine's Road, Littlehampton BN17 5HS (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,

(54) Title: PHARMACEUTICAL SALTS OF A CHK-1 INHIBITOR

(57) Abstract: The invention provides a pharmaceutically acceptable salt of 5-[[5-[4-(4-fluoro-1-methyl-4-piperidyl)-2-methoxy-phenyl]-1H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile which is selected from maleate, tosylate, besylate and malonate salts. Also provided are particular crystalline forms of the salts, methods for the preparation of the salts, pharmaceutical compositions containing the salts and their therapeutic uses.

WO 2022/253907 A1